Predictive Oncology: Helomics to present initial findings from its analysis of UK 100,000 Genomes Project data towards its go...
October 24 2019 - 8:30AM
Predictive Oncology (NASDAQ: POAI) (“Predictive Oncology” or “the
Company”), a company focused on applying artificial intelligence
(“AI”) to personalized medicine and drug discovery, today announces
that Helomics CTO Dr. Mark Collins will speak during the scientific
session of the conference, and will participate in an invite-only
session on the expansion of the UK100K GP to 5 Million genomes.
Helomics partnered with the UK100K GP in November 2018 to
utilize whole genome and outcome data from the project to advance
its efforts to build predictive models of various cancers. The
company is leveraging its proprietary, multi-omic database of tumor
drug response profiles using the proven power of AI to build
predictive models of ovarian cancer. These AI-driven predictive
models will be used by clinicians to individualize treatment
options and by pharma researchers to develop new targeted therapies
in the quest to improve outcomes for women with ovarian cancer.
“This partnership is key to our approach of building AI-driven
predictive models. We are delighted to participate in the
scientific spotlight session, panel discussion and an invite-only
session on the expansion of the UK 100,000 Genomes Project to 5
million genomes,” stated Dr. Collins. “The depth of both the
genomic and clinical data for ovarian cancer from the project is
best-in-class, yielding useful benchmarks to validate our models.
Over the next year, we intend to explore additional projects to
enable use of our AI-driven predictive models to improve outcomes
for ovarian cancer patients in the UK, as well as seek partnerships
with UK pharma companies for the development of new precision
ovarian cancer therapies.”
The inaugural UK 100,000 Genomes Project (“UK100K GP”)
conference is hosted by Genomics England, taking place Nov. 4,
2019, in London. UK100K GP is a groundbreaking initiative
sequencing whole genomes of National Health Service patients with
rare diseases and their families, as well as patients with common
cancers. The aim is to transform healthcare through new diagnoses
and personalized treatments.
According to a research report by Global Market Insights Inc.,
the precision medicine market is set to exceed US$96 billion by
2024. Helomics continues to be an innovative precision medicine
company positioned for continued growth in this robust
market.
About the 100,000 Genomes ProjectThe 100,000
Genomes Project is a UK Government project that is sequencing whole
genomes from National Health Service patients. The project is
focusing on rare diseases, some common types of cancer and
infectious diseases. Recruitment of participants to the 100,000
Genomes Project was completed in 2018, with the 100,000th sequence
achieved in December 2018.
Combining genomic sequence data with medical records has created
a ground-breaking research resource in the quest to bring advanced
diagnosis and personalized treatments to all those who need them.
To date, actionable findings have been found for one in four/one in
five rare disease patients, and around 50% of cancer cases contain
the potential for a therapy or a clinical trial.
About Predictive Oncology
Predictive Oncology (NASDAQ: POAI) is an AI-driven company
focused on applying artificial intelligence to personalized
medicine and drug discovery. The company applies smart tumor
profiling and its AI platform to extensive genomic and biomarker
patient data sets to predict clinical outcomes and, most
importantly, improve patient outcomes for cancer patients of today
and tomorrow.
Predictive Oncology currently has approximately 150,000
clinically validated cases on its molecular information platform,
38,000+ specific to ovarian cancer. The company’s data is highly
differentiated, having both drug response data and access to
historical outcome data from patients. Predictive Oncology intends
to generate additional sequence data from these tumor samples to
deliver on the clear unmet market need across the pharmaceutical
industry for a multi-omic approach to new drug development.
For more information, visit the company’s website at
www.predictive-oncology.com.
Corporate Communications:NetworkWire (NW)New
York, New Yorkwww.NetworkNewsWire.com212.418.1217
OfficeEditor@NetworkWire.com
Gerald Vardzel Jr.Helomics Corporation, PresidentA division of
Predictive Oncology Inc.91 43rd Street, Suite 110Pittsburgh,
Pennsylvania 15201412.432.1508gvardzel@helomics.com
Forward-Looking Statements
Certain of the matters discussed in the press release contain
forward-looking statements that involve material risks to and
uncertainties in the Company’s business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include (i)
risks related to the recent merger with Helomics, including the
fact that the combined company will not be able to continue
operating without additional financing; possible failure to realize
anticipated benefits of the merger; costs associated with the
merger may be higher than expected; the merger may result in
disruption of the Company’s and Helomics’ existing businesses,
distraction of management and diversion of resources; and the
market price of the Company’s common stock may decline as a result
of the merger; (ii) risks related to our partnerships with other
companies, including the need to negotiate the definitive
agreements; possible failure to realize anticipated benefits of
these partnerships; and costs of providing funding to our partner
companies, which may never be repaid or provide anticipated
returns; and (iii) other risks and uncertainties relating to the
Company that include, among other things, current negative
operating cash flows and a need for additional funding to finance
our operating plan; the terms of any further financing, which may
be highly dilutive and may include onerous terms; unexpected costs
and operating deficits, and lower than expected sales and revenues;
sales cycles that can be longer than expected, resulting in delays
in projected sales or failure to make such sales; uncertain
willingness and ability of customers to adopt new technologies and
other factors that may affect further market acceptance, if our
product is not accepted by our potential customers, it is unlikely
that we will ever become profitable; adverse economic conditions;
adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or
retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as
well as our ability to possibly license from others patents and
patent applications necessary to develop products; Predictive
Oncology’s ability to implement its long range business plan for
various applications of its technology; Predictive Oncology’s
ability to enter into agreements with any necessary marketing
and/or distribution partners and with any strategic or joint
venture partners; the impact of competition, the obtaining and
maintenance of any necessary regulatory clearances applicable to
applications of Predictive Oncology’s technology; and management of
growth and other risks and uncertainties that may be detailed from
time to time in the Company’s reports filed with the SEC, which are
available for review at www.sec.gov. This is not a solicitation to
buy or sell securities and does not purport to be an analysis of
Predictive Oncology’s financial position. See Predictive Oncology’s
most recent Annual Report on Form 10-K, and subsequent reports and
other filings at www.sec.gov.
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024